← Back to directory

Walter P. Maksymowych

Researcher Next ID · RN-031930

Researcher · Immunology and Microbiology

University of Alberta

Edmonton, Canada

Accepting doctoral researchersFunding unknown
Works count
893
Citation count
38,587
H-index
93
i10-index
372

Research interests

Immunology and Microbiology
Medicine
Spondyloarthritis Studies and Treatments
Rheumatoid Arthritis Research and Therapies
Bone and Joint Diseases
Spine and Intervertebral Disc Pathology
Psoriasis: Treatment and Pathogenesis

Publications

  • Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement

    Annals of the Rheumatic Diseases · 2020 · https://doi.org/10.1136/annrheumdis-2020-218398

  • 2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis

    Arthritis Care & Research · 2019 · https://doi.org/10.1002/acr.24025

  • 2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis

    Arthritis & Rheumatology · 2019 · https://doi.org/10.1002/art.41042

  • Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial

    The Lancet · 2018 · https://doi.org/10.1016/s0140-6736(18)32463-2

  • Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial

    The Lancet · 2018 · https://doi.org/10.1016/s0140-6736(18)31946-9

  • Defining active sacroiliitis on MRI for classification of axial spondyloarthritis: update by the ASAS MRI working group

    Annals of the Rheumatic Diseases · 2016 · https://doi.org/10.1136/annrheumdis-2015-208642

  • Major histocompatibility complex associations of ankylosing spondylitis are complex and involve further epistasis with ERAP1

    Nature Communications · 2015 · https://doi.org/10.1038/ncomms8146

  • American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network 2015 Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis

    Arthritis & Rheumatology · 2015 · https://doi.org/10.1002/art.39298

  • Symptomatic Efficacy of Etanercept and Its Effects on Objective Signs of Inflammation in Early Nonradiographic Axial Spondyloarthritis: A Multicenter, Randomized, Double‐Blind, Placebo‐Controlled Trial

    Arthritis & Rheumatology · 2014 · https://doi.org/10.1002/art.38721

  • Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study

    Annals of the Rheumatic Diseases · 2013 · https://doi.org/10.1136/annrheumdis-2013-204231

  • Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1)

    Annals of the Rheumatic Diseases · 2012 · https://doi.org/10.1136/annrheumdis-2012-201766

  • Interaction between ERAP1 and HLA-B27 in ankylosing spondylitis implicates peptide handling in the mechanism for HLA-B27 in disease susceptibility

    Nature Genetics · 2011 · https://doi.org/10.1038/ng.873

  • 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis

    Annals of the Rheumatic Diseases · 2011 · https://doi.org/10.1136/ard.2011.151027

  • 2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis

    Annals of the Rheumatic Diseases · 2011 · https://doi.org/10.1136/ard.2011.151563

  • Genome-wide association study of ankylosing spondylitis identifies non-MHC susceptibility loci

    Nature Genetics · 2010 · https://doi.org/10.1038/ng.513

  • The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part I): classification of paper patients by expert opinion including uncertainty appraisal

    Annals of the Rheumatic Diseases · 2009 · https://doi.org/10.1136/ard.2009.108217

  • New criteria for inflammatory back pain in patients with chronic back pain: a real patient exercise by experts from the Assessment of SpondyloArthritis international Society (ASAS)

    Annals of the Rheumatic Diseases · 2009 · https://doi.org/10.1136/ard.2008.101501

  • Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 years

    Arthritis Research & Therapy · 2009 · https://doi.org/10.1186/ar2794

  • The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection

    Annals of the Rheumatic Diseases · 2009 · https://doi.org/10.1136/ard.2009.108233

  • The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis

    Annals of the Rheumatic Diseases · 2009 · https://doi.org/10.1136/ard.2008.104018

  • Spondyloarthritis research Consortium of Canada magnetic resonance imaging index for assessment of sacroiliac joint inflammation in ankylosing spondylitis

    Arthritis Care & Research · 2005 · https://doi.org/10.1002/art.21445

Current projects

    No projects listed.